Cellulite-derived skin imperfections and localised adiposity at level of thighs/hip/waistline Nutritional, Metabolic, Endocrine Cellulite and localised adiposity
Conditions
Interventions
60 healthy female participants were randomly allocated evenly into either the treatment or placebo group using a computer generated restricted randomisation list. Participants in the treatment group t
Sponsors
ROELMI HPC Srl
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Good general health 2. Female 3. Caucasian ethnicity 4. Age between 18 and 55 years old 5. Mild to moderate cellulite-derived skin imperfections (grade II and III of the cellulite thermographic stage) 6. BMI between 23 and 30. 7. Not been recently involved in any other similar study 8. Willing to follow the proposed alimentary diet for all the study time 9. Willing to use only the cream consigned at the beginning of the study for body care 10. Willing to submit to before and after pictures 11. Willing to use only the food supplement during the entire study period 12. Willing to not use products likely to interfere with the food supplement 13. Willing to not vary the normal daily routine (i.e. lifestyle, physical activity, etc.) 14. Under effective contraception (oral/not oral) that is not expected to be changed during the trial 15. Aware of study procedures and signed informed consent form
Exclusion criteria
Exclusion criteria: 1. Pregnant or intending to become pregnant during study 2. Breastfeeding 3. Atopy (if this interferes with the study) 4. Allergic to ingredients of food supplements 5. Allergies to cosmetic products, toiletries, sunscreens and/or topical drugs 6. Following anti-cellulite treatment or have followed an anti-cellulite treatment less than 3 months before the study 7. Used sunbeds or self-tanning product for one month before study or intend to use it during the study 8. Using pharmacological treatment (local or systemic) that may interfere with study 9. Intending to initiate any intensive sport 10. Other diseases that may affect outcome of study, especially metabolic or endocrine (e.g. diabetes, liver disease, kidney disorders) or any other condition that the principal investigator deems inappropriate for participation 11. Protected by the law (under guardianship, hospitalised in a public or private institution or incarcerated) 12. Unable to communicate or cooperate with the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The following outcomes were measured at day 0 (beginning of the treatment), day 28 and day 56 of treatment: 1. Cellulite-induced alteration of the skin microcirculation, measured by thermographic imaging 2. Clinical-dermatological evaluation of the cellulite-derived skin imperfections ("Orange peel" skin appearance ) carried out by a dermatologist in accordance to clinical scores 3. Thickness of the subcutaneous fatty layer measured by an ultrasound technique (using BX2000 BodyMetrix) 4. Skin elasticity and firmness, measured on the thighs by a Cutometer® | — |
Secondary
| Measure | Time frame |
|---|---|
| The following outcomes were measured at day 0 (beginning of the treatment), day 28 and day 56 of treatment: 1. Body weight by electric balance and height by stadiometer (for BMI determination) 2. Body circumferences (tights, hips, waistline) by a flexible meter 3. Evaluation of safety (adverse effects and tolerability) by monitoring adverse effects 4. Self-assessment evaluation, assessed using a 12 question questionnaire carried out after 28 and 56 days of treatment | — |
Countries
Italy
Outcome results
None listed